Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.

Published in: The Annals of pharmacotherapy (2023)

Sotorasib and adagrasib demonstrated promising outcomes in targeting the constitutively active KRAS G12C oncogenic driver, underscoring the need for further research to optimize their therapeutic application in this high-risk population.

Keyphrases

wild type
cancer therapy
transcription factor
type diabetes
skeletal muscle
drug delivery